Jeanette Dilan-Koetje
Internal Medicine · Eldon, MONPI 1538499454
Payments from drug & device makers
Across 86 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$250
- Novo Nordisk$223
- AbbVie$184
- Lilly USA, LLC$151
- AstraZeneca$129
- Pfizer$65
- plus $456 from 12 others
What the payments were for
- Food & beverage$1,458100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 16 | $250 |
| Novo Nordisk | 12 | $223 |
| AbbVie | 11 | $184 |
| Lilly USA, LLC | 8 | $151 |
| AstraZeneca | 8 | $129 |
| Pfizer | 4 | $65 |
| Exact Sciences | 4 | $64 |
| Dexcom, Inc. | 3 | $62 |
| Phathom Pharmaceuticals, Inc. | 4 | $59 |
| Merck | 3 | $58 |
| Otsuka America Pharmaceutical, Inc. | 3 | $48 |
| Boehringer Ingelheim | 2 | $36 |
| Mylan Specialty L.p. | 2 | $31 |
| Novartis | 2 | $30 |
| Radius Health, Inc. | 1 | $20 |
| GSK | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Verona Pharma, Inc. | 1 | $14 |
How this compares
$1,458 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 95 | $102,084 |
| OzempicSemaglutide | 60 | $54,720 |
| JardianceEmpagliflozin | 39 | $43,984 |
| EliquisApixaban | 44 | $40,319 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $14,536 |
| JanuviaSitagliptin Phosphate | 11 | $10,835 |
| Pregabalin | 41 | $2,456 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 57 | $1,779 |
| Varenicline Tartrate | 13 | $1,704 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,445 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $1,333 |
| Pantoprazole Sodium | 88 | $1,307 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,191 |
| Duloxetine Hcl | 40 | $1,067 |
| Levothyroxine Sodium | 121 | $1,020 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $151 | $102,08495 claims |
| Novo NordiskOzempic | $223 | $54,72060 claims |
| Boehringer IngelheimJardiance | $36 | $43,98439 claims |
| PfizerEliquis | $65 | $40,31944 claims |
| GSKTrelegy Ellipta | $17 | $14,53619 claims |
| MerckJanuvia | $58 | $10,83511 claims |
| AbbVieSynthroid | $184 | $74614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Eldon
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.